Month: June 2020

Frontline pembrolizumab doubled progression-free survival (PFS), when compared with chemotherapy, among patients with microsatellite instability–high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer in the KEYNOTE-177 study. The median PFS was 16.5 months for patients who received pembrolizumab and 8.2 months for those who received investigators’ choice of chemotherapy (one of six regimens). “In the past, no medical
0 Comments
FDA Approves Oriahnn (elagolix/estradiol/norethindrone acetate and elagolix) for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-Menopausal Women Print this page NORTH CHICAGO, Ill., May 29, 2020 /PRNewswire/ — AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (Nasdaq: NBIX), announced that the U.S. Food and Drug Administration (FDA) approved Oriahnn (elagolix,
0 Comments
Welcome to this week’s edition of Healthcare Career Insights. This weekly roundup highlights healthcare career-related articles culled from across the Web to help you learn what’s next. Lisa Grabl is president of the locum tenens division of CompHealth, the nation’s largest locum tenens physician staffing company and a leader in permanent and temporary allied healthcare
0 Comments